Revenue · 2016–2025

Alnylam Pharmaceuticals revenue

$3.7B+65.2% · FY2025

Alnylam Pharmaceuticals (ALNY) reported $3.7B in revenue for fiscal 2025, +65.2% year on year.

$47.2M2016$89.9M2017$74.9M2018$220M2019$493M2020$844M2021$1.0B2022$1.8B2023$2.2B2024$3.7B2025
Alnylam Pharmaceuticals — Revenue, 2016–2025
Fiscal yearRevenueChangeFiling
FY20252025-12-31$3.7B+65.2%Open →
FY20242024-12-31$2.2B+23.0%Open →
FY20232023-12-31$1.8B+76.2%Open →
FY20222022-12-31$1.0B+22.9%Open →
FY20212021-12-31$844M+71.3%Open →
FY20202020-12-31$493M+124.3%Open →
FY20192019-12-31$220M+193.4%Open →
FY20182018-12-31$74.9M−16.7%Open →
FY20172017-12-31$89.9M+90.7%Open →
FY20162016-12-31$47.2M—Open →

Revenue — Revenue is total net sales for the fiscal year, taken from each company's own annual filing.

Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2016–2025 compound annual growth +62.4%

Revenue at companies of similar size

Full ranking by revenue →

Cite this page

Ready-made references for the figures on this page, as published on September 25, 2026.

Wikipedia

{{cite web |title=Alnylam Pharmaceuticals revenue |url=https://companiesranked.com/en/company/alnylam-pharmaceuticals/revenue |website=CompaniesRanked |date=2026-09-25 |language=en}}

APA 7

CompaniesRanked. (September 25, 2026). Alnylam Pharmaceuticals revenue. CompaniesRanked. https://companiesranked.com/en/company/alnylam-pharmaceuticals/revenue

BibTeX

@misc{companiesranked-en-company-alnylam-pharmaceuticals-revenue-2026,
  author       = {{CompaniesRanked}},
  title        = {{Alnylam Pharmaceuticals revenue}},
  year         = {2026},
  howpublished = {\url{https://companiesranked.com/en/company/alnylam-pharmaceuticals/revenue}},
  note         = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
  urldate      = {2026-09-25}
}

The filing itself

The numbers above are read from this document: 10-K · 0001628280-26-007497 · February 12, 2026

{{cite web |title=Alnylam Pharmaceuticals revenue — 10-K (0001628280-26-007497) |url=https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-12}}

The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.

← Alnylam Pharmaceuticals overview